• About us
• Contact

Advertisement

Organisation › Details

NeoSphere Biotechnologies GmbH

NEOsphere Biotechnologies is a leader in proteomics for targeted protein degradation drug discovery. Its unique target and E3 ligase-agnostic deep proteomic screening platform combines world-class mass spectrometry with expert data analysis to advance and characterize all types of protein degraders and stabilizers in native cells and to identify molecules that act through new E3 ligases and novel TPD mechanisms. This systematic approach creates broad pipelines of novel, high-value degrader targets at scale and advances its partners’ TPD drug discovery programs at all stages. NEOsphere Biotechnologies’ global ubiquitinomics platform rapidly mechanistically validates target candidates and confirms degrader induced modification to an unparalleled depth. Automated processes and exceptional high-throughput capabilities ensure maximum proteome coverage, accuracy, precision and data completeness, with short turnaround times compatible with drug optimization cycles. NEOsphere Biotechnologies’ intuitive and user-friendly data analysis applications visualize even large proteomics datasets for immediate access, enabling informed decisions in drug discovery, SAR optimization, target identification, and library expansion. *

 

	Start	2022-04-15 renamed
	Predecessor	Como Biotech GmbH
	Industry	mass spectrometry-based proteomics
	Person	Jenne, Andreas (RSP Systems 201805– CEO before NEO New Oncology + Blackfield + Kinaxo)
	Person 2	Fritz, Jutta (NanoSphere Biotechnologies 202207 CBO before Blackfield + Kinaxo+ Max Planck Innovation)
	Region	Martinsried
	Country	Germany
	Street	1 Fraunhoferstr.
	City	82152 Planegg
	Tel	+49-89-4378020-0
		Address record changed: 2024-05-14
Basic data	Employees	n. a.
		* Document for »About Section«: NeoSphere Biotechnologies GmbH. (5/14/24). "Press Release: NeoSphere Biotechnologies Partners with Kymera Therapeutics for Novel Molecular Glue Target Discovery". Martinsried.
		Record changed: 2024-05-14

Advertisement

More documents for NeoSphere Biotechnologies GmbH

• [1] NeoSphere Biotechnologies GmbH. (7/25/22). "Press Release: NeoSphere Biotechnologies Closes Financing Round to Expand Proteomics Platform for Systematic Identification of Novel Targets for Targeted Protein Degradation". Munich....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.